BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Trial Details

NCT ID
NCT07625644
Phase
PHASE3
Sponsor
SystImmune Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BL-M14D1 and Atezolizumab
  • Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
Locations (sample)
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • Glendale, California, United States|34.14251,-118.25508
  • Miami, Florida, United States|25.77427,-80.19366
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)
  • Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.
  • At least one measurable lesion based on RECIST v1.1 per investigator assessment.
  • An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →